OXFORD BIOMEDICA Trademark

Trademark Overview


On Wednesday, June 14, 2017, a trademark application was filed for OXFORD BIOMEDICA with the United States Patent and Trademark Office. The USPTO has given the OXFORD BIOMEDICA trademark a serial number of 87488957. The federal status of this trademark filing is REGISTERED as of Tuesday, April 24, 2018. This trademark is owned by Oxford BioMedica (UK) Limited. The OXFORD BIOMEDICA trademark is filed in the Chemical Products, Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing retroviral vector preparations and/or nucleic acid suitable for gene therapy; retroviral vector preparations for use in gene therapy; pharmaceutical preparations containing a retroviral vector delivering genes to cells for use in the treatment of viral and bacterial infections, cancer, HIV and AIDS, neurodegenerative diseases, diseases of the eye, leukemia and bodily conditions associated with impaired immunosystems; Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals; small molecules, vaccines, biologics, enzymes and enzyme preparations all for medical treatment purposes; pharmaceuticals for medical purposes for the delivery of genes to cells; viral, retroviral and non-viral vectors, all for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious ...

Chemical compositions containing nucleic acids for use in the manufacture of pharmaceuticals and retroviral vector preparations; Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicals, namely, precursors for in vitro genetic engineering use; polypeptides for in vitro research use, monoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research use, viruses for laboratory and scientific research use, cell cultures for laboratory and scientific research use, plasmids and cultures of micro-organisms for laboratory and scientific research use, nucleic acid sequences for laboratory and scientific...

Medical services; advisory services relating to vaccination regimes; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, ...

Scientific, pharmaceutical and medical research and development; genetic engineering services, biotechnology services, namely, research and development for new products in the field of biotechnology, advisory services relating to gene therapy products and clinical trials, conducting clinical trials
oxford biomedica

General Information


Serial Number87488957
Word MarkOXFORD BIOMEDICA
Filing DateWednesday, June 14, 2017
Status700 - REGISTERED
Status DateTuesday, April 24, 2018
Registration Number5451207
Registration DateTuesday, April 24, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 7, 2017

Trademark Statements


Goods and ServicesClinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing retroviral vector preparations and/or nucleic acid suitable for gene therapy; retroviral vector preparations for use in gene therapy; pharmaceutical preparations containing a retroviral vector delivering genes to cells for use in the treatment of viral and bacterial infections, cancer, HIV and AIDS, neurodegenerative diseases, diseases of the eye, leukemia and bodily conditions associated with impaired immunosystems; Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals; small molecules, vaccines, biologics, enzymes and enzyme preparations all for medical treatment purposes; pharmaceuticals for medical purposes for the delivery of genes to cells; viral, retroviral and non-viral vectors, all for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes; pre-filled vials for medical purposes and for pharmaceutical and biochemical preparations, for use in gene therapy and for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders
Goods and ServicesChemical compositions containing nucleic acids for use in the manufacture of pharmaceuticals and retroviral vector preparations; Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicals, namely, precursors for in vitro genetic engineering use; polypeptides for in vitro research use, monoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research use, viruses for laboratory and scientific research use, cell cultures for laboratory and scientific research use, plasmids and cultures of micro-organisms for laboratory and scientific research use, nucleic acid sequences for laboratory and scientific research use, cloning vehicles in the nature of plasmids, microbes and chemical reagents for DNA cloning for laboratory and scientific research use, chemicals for laboratory, scientific and biotechnology research and development and recombinant nucleic acid variations thereof for laboratory and scientific research use, namely, in vitro and in vivo use
Goods and ServicesMedical services; advisory services relating to vaccination regimes; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders and contraceptives
NOT AVAILABLE"OXFORD"
Goods and ServicesScientific, pharmaceutical and medical research and development; genetic engineering services, biotechnology services, namely, research and development for new products in the field of biotechnology, advisory services relating to gene therapy products and clinical trials, conducting clinical trials

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateWednesday, June 21, 2017
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, June 21, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, June 21, 2017
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, June 21, 2017
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameOxford BioMedica (UK) Limited
Party Type30 - Original Registrant
Legal Entity Type11 - Company
AddressOxford OX4 6LT
GB

Party NameOxford BioMedica (UK) Limited
Party Type20 - Owner at Publication
Legal Entity Type11 - Company
AddressOxford OX46LT
GB

Party NameOxford BioMedica (UK) Limited
Party Type10 - Original Applicant
Legal Entity Type11 - Company
AddressOxford OX46LT
GB

Trademark Events


Event DateEvent Description
Monday, September 18, 2017NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Saturday, June 17, 2017NEW APPLICATION ENTERED
Wednesday, June 21, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 13, 2017ASSIGNED TO EXAMINER
Monday, September 18, 2017EXAMINERS AMENDMENT -WRITTEN
Monday, September 18, 2017EXAMINER'S AMENDMENT ENTERED
Monday, September 18, 2017EXAMINERS AMENDMENT E-MAILED
Tuesday, March 20, 20181(B) BASIS DELETED; PROCEED TO REGISTRATION
Monday, September 18, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Sunday, October 1, 2017ASSIGNED TO LIE
Wednesday, October 18, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 7, 2017PUBLISHED FOR OPPOSITION
Tuesday, November 7, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 2, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 6, 2018TEAS DELETE 1(B) BASIS RECEIVED
Tuesday, March 6, 2018NOTICE OF ALLOWANCE CANCELLED
Tuesday, March 20, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, April 24, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Thursday, October 17, 2024TEAS SECTION 8 & 15 RECEIVED
Friday, June 8, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, April 24, 2018REGISTERED-PRINCIPAL REGISTER
Friday, June 8, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED